

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 35/14, 35/28	A1	(11) International Publication Number: WO 97/17079 (43) International Publication Date: 15 May 1997 (15.05.97)
(21) International Application Number: PCT/US96/12426 (22) International Filing Date: 29 July 1996 (29.07.96) (30) Priority Data: 08/555,520 8 November 1995 (08.11.95) US (60) Parent Application or Grant (63) Related by Continuation US 08/555,520 (CIP) Filed on 8 November 1995 (08.11.95) (71) Applicant (for all designated States except US): EMORY UNIVERSITY [US/US]; 2009 Ridgewood Drive, Atlanta, GA 30322 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): WALLER, Edmund, K. [US/US]; 890 Los Angeles Avenue, N.E., Atlanta, GA 30306 (US). (74) Agents: PERRYMAN, David, G. et al.; Needle & Rosenberg, Suite 1200, 127 Peachtree Street, N.E., Atlanta, GA 30303-1811 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: METHOD OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITHOUT GRAFT FAILURE OR GRAFT VS. HOST DISEASE (57) Abstract The present invention provides a method of transplanting hematopoietic system reconstituting cells from a donor into an allogeneic recipient comprising administering to the recipient, prior to the administration of the hematopoietic system reconstituting cells, an amount of mononuclear cells which are treated so as to render them incapable of proliferating and causing a lethal graft versus host disease effect, but which are effective in enhancing subsequent engraftment of the hematopoietic system reconstituting cells in the recipient; and administering to the recipient an effective amount of hematopoietic system reconstituting cells.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**METHOD OF ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION WITHOUT
GRAFT FAILURE OR GRAFT VS. HOST DISEASE**

5

BACKGROUND OF THE INVENTION

FIELD OF THE INVENTION

The present invention relates to a method of transplanting hematopoietic system
10 reconstituting cells between genetically unrelated individuals using a combination of
treated mononuclear cells and bone marrow or peripheral blood hematopoietic system
reconstituting cells.

BACKGROUND ART

15

Allogeneic bone marrow transplantation is the preferred treatment for a variety
of malignant and genetic diseases of the blood and blood-forming cells. The widespread
application of this therapy is limited by the availability of suitable bone marrow donors
who are genetically related to the patient and share the same transplantation antigens on
20 the surface of their blood cells. Only 25% of patients have a sibling who is an
antigenically matched potential donor. Bone marrow transplantation can be offered to
those patients who lack an appropriate sibling donor by using bone marrow from
antigenically matched, genetically unrelated donors (identified through a national
registry), or by using bone marrow from a genetically related sibling or parent whose
25 transplantation antigens differ by one to three of six human leukocyte antigens from
those of the patient. However, using antigenically mismatched, genetically related
parent or sibling or antigenically matched, genetically unrelated donors, the likelihood of
fatal graft vs. host disease (GvHD) and/or graft rejection increases from 20% for
matched sibling donors to 50% in the cases of matched, unrelated donors and un-
30 matched donors from the patient's family. Further, in cases where an unrelated donor is
not matched at one of the six major transplantation antigens, graft rejection and/or fatal
GvHD increases to 60%.

GvHD is a disease with significant morbidity. Patients who develop acute GvHD may develop blisters covering most of their skin surface, massive gastrointestinal bleeding or fulminant liver failure and jaundice. Patients who develop chronic GvHD may develop scleroderma that results in joint contractures and skin ulcers, hair loss and a generalized wasting syndrome. Patients with acute or chronic GvHD are immuno-suppressed and at risk for life-threatening opportunistic infections similar to those that develop among AIDS patients.

The removal of T cells from the bone marrow obtained from matched unrelated or unmatched sibling donors results in a decreased incidence of graft vs. host reactions, but an increased incidence of rejection of the allogeneic bone marrow graft by the patient. Thus, lymphocytes, and especially T cells, present in the allogeneic bone marrow graft are important to ensure engraftment in antigenically and genetically mismatched recipients. T cells present in the allogeneic graft also have an important role in eliminating residual cancer cells in the recipient, a phenomenon termed "graft vs. leukemia effect." The "ideal" donor T cell in an allogeneic bone marrow or stem cell graft would have the ability to prevent graft rejection and mediate the graft vs. leukemia effect without producing GvHD. The potential to successfully transplant T cell-depleted, or stem cell-enriched bone marrow or stem cells from antigenically mismatched donors to patients without graft rejection or GvHD would greatly extend the availability of bone marrow transplantation to those patients without an antigenically matched sibling donor.

In a dog model of allogeneic bone marrow transplantation, the addition of viable donor lymphocytes to the bone marrow graft resulted in an increased frequency of stable engraftment, from 9% using antigenically mis-matched bone marrow alone, to 88%, using a combination of bone marrow and donor lymphocytes. However, all the animals that received donor lymphocytes died of lethal GvHD (Storb *et al.* (1968) "Marrow grafts by combined marrow and leucocyte infusions in unrelated dogs selected by histocompatibility typing" *Transplantation* 6:587-593).

An alternative to infusions of viable donor lymphocytes has been the use of irradiated donor lymphocytic infusions in the post-transplant period. The addition of donor lymphocytes that had been previously irradiated to a dose of 20 cGy (2,000 rads) to allogeneic bone marrow cells did not prevent fatal graft failure when the mixture was administered to lethally irradiated dogs antigenically mismatched for dog leukocyte antigens (DLA), (Deeg *et al.* (1979) "Abrogation of resistance to and enhancement of DLA-nonidentical unrelated marrow grafts in lethally irradiated dogs by thoracic duct lymphocytes", *Blood* 53:552-587).

10 In genetically unrelated rabbits, a series of five infusions of donor lymphocytes, irradiated to 15cG (1,500 rads) one to ten days following the infusion of allogeneic bone marrow cells and irradiated autologous bone marrow cells decreased the rate of graft rejection from 60% to 20%, but only 30% of the treated animals survived more than 100 days with donor derived hematopoietic cells and 40% of animals that received T cell depleted bone marrow followed by irradiated allogenic lymphocytes developed GvHD. 15 (Gratwohl *et al.* (1987) "Engraftment of T-cell depleted rabbit bone marrow" *Acta haematol.* 77:208-214).

The addition of antigenically matched viable donor lymphocytes obtained from the bone marrow donor and given 1-5 days post-transplant to 43 patients undergoing allogeneic bone marrow transplantation for aplastic anemia resulted in a 14% incidence of graft failure compared to 22% in a similar group of 20 patients who received the bone marrow transplant without additional donor lymphocytes, to 14% in the group that received post-transplant donor lymphocytes. However, the incidence of acute GvHD 25 was 36% in the group treated with donor lymphocytes compared to a 20% incidence of acute GvHD in the group that received bone marrow cells alone. In both groups, 20% of patients ultimately died of GvHD, (Storb *et al.* (1982) "Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients", *Blood* 59:236-246).

In a clinical report describing the use of irradiated human lymphocytes, 20 patients with hematological malignancies were treated with high-dose chemotherapy and total body irradiation followed by the infusion of T cell-depleted antigenically matched, genetically related allogeneic bone marrow cells. One, three, five, seven and fourteen
5 days following bone marrow transplantation, the patients received infusions of donor lymphocytes, irradiated to 15cGy (1,500 rads). The authors reported no cases of graft failure, but noted an overall incidence of GvHD of 85% and a 15% incidence of fatal GvHD, (Gratwohl *et al.* (1988) "Irradiated donor buffy coat following T cell-depleted bone marrow transplants", *Bone marrow transplantation* 3:577-582).

10

These reports suggest that infusions of irradiated donor lymphocytes are not toxic to recipients of bone marrow transplantation, but do not demonstrate clear efficacy in either preventing graft rejection or GvHD. The present invention overcomes the problems in the art by providing a method of transplanting hematopoietic system
15 reconstituting cells from a donor to an antigenically matched or unmatched, genetically unrelated recipient or an antigenically unmatched, genetically related recipient with successful engraftment in the absence of GvHD.

SUMMARY OF THE INVENTION

20

The present invention provides a method of transplanting hematopoietic system reconstituting cells from a donor into an allogeneic recipient comprising administering to the recipient, prior to the administration of the hematopoietic system reconstituting cells, an amount of mononuclear cells which are treated so as to render them incapable of
25 proliferating and causing a lethal GvHD effect, but which are effective in enhancing subsequent engraftment of the hematopoietic system reconstituting cells in the recipient; and administering to the recipient an effective amount of hematopoietic system reconstituting cells.

30

In a specific embodiment, the present invention provides a method of transplanting bone marrow cells into an allogeneic recipient comprising administering to

the recipient, one to five days prior to administration of the bone marrow cells, between 0.05×10^6 and 30×10^6 cells/kg of body weight of T cells that have been exposed to between 500 and 1000 rads of irradiation; and administering to the recipient between 1.0×10^8 and 4×10^8 T cell-depleted bone marrow cells/kg of body weight.

5

DETAILED DESCRIPTION OF THE EMBODIMENTS

The present invention may be understood more readily by reference to the following detailed description of specific embodiments and the Examples included
10 herein.

In one embodiment, the present invention provides a method of transplanting hematopoietic system reconstituting cells from a donor source into an allogeneic recipient comprising administering to the recipient, prior to the administration of the
15 hematopoietic system reconstituting cells, an amount of mononuclear cells which are treated so as to render them incapable of proliferating and causing a lethal GvHD effect, but which are effective in enhancing subsequent engraftment of the hematopoietic system reconstituting cells in the recipient; and administering to the recipient an effective amount of hematopoietic system reconstituting cells.

20

As used herein, "hematopoietic system reconstituting cells" means a population of cells, preferably human, that possess the capability of dividing and producing progeny that include all of the formed cellular elements of the blood. As used herein, "donor source" means the animal, preferably human, that is the natural source from which the
25 hematopoietic system reconstituting cells are originally removed. Also as used herein, a "recipient" is the animal, typically human, into which the hematopoietic system reconstituting cells will be transplanted. The term "allogeneic" as used herein means that the recipient is not the natural source from which the hematopoietic system reconstituting cells have been removed. Major histocompatibility complex antigens
30 (also called human leukocyte antigens, HLA) are protein molecules expressed on the surface of cells that confer a unique antigenic identity to these cells. MHC/HLA

antigens are target molecules that are recognized by certain immune effector cells [(T-cells and natural killer (NK cells)] as being derived from the same source of hematopoietic reconstituting stem cells as the immune effector cells ("self") or as being derived from another source of hematopoietic reconstituting cells ("non-self").

5

Mononuclear cells are cells of the hematopoietic system identified by a round, nonsegmented nucleus. Mononuclear cells can include T cells, NK cells, monocytes, mixtures of T cells, NK cells or monocytes.

10 Properties of T cells include the expression of a complex of proteins on their cell surfaces that include the CD3 antigen and the T cell receptor (TCR) that can bind to MHC/HLA molecules expressed on the surface of other cells. The presence of the CD3/TCR complex allows T cells to recognize cells from genetically different individuals as expressing "non-self" MHC/HLA antigens and to recognize virally
15 infected cells and tumor cells from the same individual as expressing "altered self" MHC/HLA antigens. T cells are able to bind to and kill cells that express "non-self" and "altered self" MHC/HLA by the activation of specific cytolytic enzymes; they regulate (including stimulation and inhibition) T cell and B cell proliferation and antibody production in response to a specific antigen; they release protein molecules called
20 cytokines that stimulate or inhibit the immune response; and they undergo multiple rounds of cell division and produce daughter cells with similar biologic properties as the parent cell. Examples of T cells with some attributes of NK cells include cells that express both the CD3 (T cell specific) and the CD56 (NK cell specific) antigens.

25 Properties of NK cells include: the expression of antigens on their cell surface that include one or more of the following: CD16, CD56, and CD57 and the absence of the alpha/beta or gamma/delta TCR complex expressed on the cell surface; the ability to bind to and kill cells that fail to express "self" MHC/HLA antigens by the activation of specific cytolytic enzymes; the ability to kill tumor cells from a genetically unrelated
30 individual; the ability to release protein molecules called cytokines that stimulate or

inhibit the immune response; and the ability to undergo multiple rounds of cell division and produce daughter cells with similar biologic properties as the parent cell.

Properties of monocytes include the ability to engulf (phagocytosis) bacteria and
5 "non-self" cells; the elaboration of cytokines that stimulate T cells and NK cells; the release of molecules that cause inflammation; and the presentation of antigens to T cells.

The mononuclear cells are "treated so as to render them incapable of proliferating and causing a lethal GvHD effect." As used herein, this phrase means that
10 the mononuclear cells can be treated, for example by exposure to a source of ionizing radiation, which will have the effect of preventing lethal GvHD. It is believed that the treatment sufficiently hinders the mononuclear cell proliferation such that they do not cause a lethal GvHD in the patient. Sources of ionizing radiation can include but are not limited to gamma radiation produced by the nuclear decay of a radio-isotope (Till and
15 McCulloch, 1961, "A direct measurement of the radiation sensitivity of normal mouse bone marrow cells", *Radiation Research*, 14:213-222) and a linear accelerator which produces high energy X-rays (Gratwohl *et al.* (1988), "Irradiated buffy coat following T cell depleted bone marrow transplants", *Bone Marrow Transplantation*, 3:577-582). Using gamma radiation as the source of the ionizing radiation, the mononuclear cells, in
20 one example, can be irradiated with between 250 and 2000 rads of radiation. An alternative range of irradiation doses is between 500 and 1500 rads of irradiation, with 500 to 1000 rads of irradiation being another range. In another example, the mononuclear cells can also be irradiated with gamma radiation using any range of any values between 250 and 5000 rads, for example, 350 and 1900, 450 and 1800, 550 and
25 1700, etc. or combinations thereof (e.g., 250 and 1900).

Alternatively, the mononuclear cells can be treated with cytotoxic chemotherapeutic drugs to render the cells incapable of proliferating and causing a lethal GvHD. Cytotoxic chemotherapeutic drugs act by cross-linking DNA or otherwise
30 interfering with normal cellular metabolism so as to render cells incapable of proliferating (Chabner (1993) "Anticancer Drugs" in *Cancer: Principles and Practice of*

Oncology, Fourth Edition, eds. DeVita, Hellman, and Rosenberg. pp. 325-417. J.B. Lippincott publishers, Philadelphia). Examples of such cytotoxic chemotherapeutic drugs that could be employed in the present invention include, but are not limited to, mitomycin C, bleomycin, actinomycin D, fludarabine, doxorubicin, daunorubicin, mitoxanthrone, cytarabine, streptozocin and amsacrine. The mononuclear cells are incubated with a sufficient concentration of the cytotoxic drug so as to result in their eventual death. For example, 5×10^7 mononuclear cells/ml can be incubated with 50 μ g/ml mitomycin C in phosphate buffered saline for 20 minutes at 37°. Mitomycin C enters the mononuclear cells and acts to cross-link DNA. Unbound mitomycin C is then removed by diluting the cell suspension with PBS, centrifuging the mixture at 300xg for 5 minutes and removing the supernatant. Fresh PBS is added to the cell pellet and the washing procedure is repeated two additional times. The cell pellet is then resuspended in PBS or a similar physiologic salt solution.

The mononuclear cells are treated, for example, by either ionizing radiation or cytotoxic chemotherapeutic drugs to render the cells substantially incapable of proliferating but such that the mononuclear cells are effective in enhancing subsequent engraftment of the hematopoietic system reconstituting cells in the recipient, for example, by neutralizing restricting host cells. This enhancement may be due to mononuclear cells conditioning the recipient to successfully accept the transplanted cells without proliferating in the recipient and mounting an immune response against the recipient's cells. The mononuclear cells can also exert a graft versus leukemia effect by which they aid in the elimination of residual cancer cells in the recipient.

The treated mononuclear cells can be administered to the recipient at any time prior to the administration of the hematopoietic system reconstituting cells and preferably are administered up to ten days prior to administration of the hematopoietic system reconstituting cells. Most preferably, the treated mononuclear cells are administered to the recipient between one and five days prior to the administration of the hematopoietic system reconstituting cells. Any range of treatment, e.g., one to nine,

two to eight, three to seven, one to two, one to three, zero to one, zero to two days, etc. are also provided.

The hematopoietic system reconstituting cells and the treated mononuclear cells
5 can be from the same donor source or they can be from different donors. These donor source cells include cells which are propagated *in vitro* or derived *in vitro* from a less differentiated cell type of the donor source, for example, from a yolk sac or other embryonic fetal tissue source such as embryonic stem cells.

10 The amount of treated mononuclear cells administered to the recipient, in one example, can be between 0.05×10^6 and 30×10^6 cells/kg of the recipient's body weight. Subranges of treated mononuclear cells are also provided, for example 5 to 25×10^6 , 10 to 20×10^6 , 5 to 20×10^6 , etc.

15 The hematopoietic system reconstituting cells administered to the recipient can, in one example, be present in a source population of between 0.2×10^8 and 4.0×10^8 , or ranges there between, donor bone marrow cells/kg of the recipient's body weight. The bone marrow cells can be obtained from the donor by standard bone marrow aspiration techniques known in the art. Bone marrow cells are removed from the donor by placing
20 a hollow needle into the marrow space and withdrawing a quantity of marrow cells by aspiration.

Alternatively, the hematopoietic system reconstituting cells administered to the recipient can, in one example, be present in a source population of between 1.0×10^8
25 and 40×10^8 , or ranges there between, donor cytokine mobilized peripheral blood stem cells/kg of recipient's body weight. Peripheral blood cells can be obtained from the donor, for example, by standard phlebotomy or apheresis techniques. Phlebotomy is performed by placing a hollow needle into a vein and withdrawing a quantity of whole blood using aspiration or gravity. Apheresis is performed in a similar manner to
30 phlebotomy except the whole blood is anticoagulated and then separated into the constituent formed cellular elements by centrifugation. The mononuclear cell fraction is

retained and the remaining plasma and other cellular elements (red blood cells, granulocytes, platelets) are returned to the patient by intravenous infusion.

Peripheral blood stem cells can be cytokine mobilized by injecting the donor with
5 hematopoietic growth factors such as Granulocyte colony stimulating factor (G-CSF),
granulocyte-monocyte colony stimulating factor (GM-CSF), stem cell factor (SCF)
subcutaneously or intravenously in amounts sufficient to cause movement of
hematopoietic stem cells from the bone marrow space into the peripheral circulation.
The hematopoietic reconstituting cells can also be derived from fetal or embryonic
10 human tissue that is processed and/or cultured *in vitro* so as to increase the numbers or
purity of primitive hematopoietic elements.

The hematopoietic system reconstituting cells administered to the recipient can
be T cell-depleted to prevent the development of GvHD. The cell population is depleted
15 of T cells by one of many methods known to one skilled in the art (Blazer *et al.*, (1985)
"Comparison of three techniques for the *ex vivo* elimination of T cells from human bone
marrow." *Experimental Hematology* 13:123-128) or by using affinity chromatography,
as described below. In addition, the hematopoietic system reconstituting cells
administered to the recipient can also be hematopoietic system cells that have been
20 enriched from the source population. The source population can be either donor bone
marrow cells or donor peripheral blood cells. The hematopoietic system reconstituting
cells can be enriched from the source population by selecting cells that express the CD34
antigen, using combinations of density centrifugation, immuno-magnetic bead
purification, affinity chromatography, and fluorescent activated cell sorting, known to
25 those skilled in the art (Baum, C.M., I.L. Weissman *et al.*, (1992) "Isolation of a
candidate human hematopoietic stem-cell population" *Proc. Natl. Acad. Sci. U.S.A.*
89:2804-8; Lansdorp, P.M., H.J. Sutherland *et al.*, (1990) "Selective expression of
CD45 isoforms on functional subpopulations of CD34+ hematopoietic cells from human
bone marrow." *J. Exp. Med.* 172:363-6; Sato, N., K. Sawada *et al.*, (1991) "Purification
30 of human marrow progenitor cells and demonstration of the direct action of macrophage
colony-stimulating factor on colony-forming unit-macrophage" *Blood* 78:967-74; Smith,

- C., C. Gasparetto *et al.*, (1991) "Purification and partial characterization of a human hematopoietic precursor population" *Blood* 77:2122-8; Udomsakdi, C., C.J. Eaves *et al.*, (1991) "Separation of functionally distinct subpopulations of primitive human hemtopoietic cells using rhodamine-123" *Exp. Hematol.* 19:338-42; Udomsakdi, C.,
- 5 P.M. Lansdorp *et al.*, (1992) "Characterization of primitive hematopoietic cells in normal human peripheral blood" *Blood* 80:2513-21.

The treated mononuclear cells and hematopoietic system reconstituting cells are typically administered to the recipient in a pharmaceutically acceptable carrier by

10 intravenous infusion. Carriers for these cells can include but are not limited to solutions of phosphate buffered saline (PBS) containing a mixture of salts in physiologic concentrations.

The recipient can be treated with antibodies or antisera intended to deplete

15 residual T cells or NK cells. Examples include the administration of 100 μ l of antiasialo antisera to mice by intravenous or intraperitoneal injection one to three days prior to the administration of allogeneic bone marrow cells, a treatment that enhances the engraftment of the mice by antigenically mismatched and genetically unrelated tumor cells (Waller *et al.* (1991) "Growth of primary T-cell non-Hodgkin's lymphomata in

20 SCID-hu mice: requirement for a human lymphoid microenvironment", *Blood* 78(10):2650-65). Another example includes the intraveneous administration of anti-thymocyte globulin to human patients one to five days prior to the intraveneous infusion of allogeneic bone marrow cells (Storb *et al.* (1994) "Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with

25 aplastic anemia", *Blood* 84(3):941-9).

In a more specific embodiment, the present invention provides a method of transplanting bone marrow cells from a donor into an allogeneic recipient comprising administering to the recipient, one to five days prior to administration of the bone

30 marrow cells, between 0.05×10^6 and 30×10^6 cells/kg of the recipient's body weight of T cells that have been exposed to between 500 and 1000 rads of gamma irradiation; and

administering to the recipient between 1.0×10^8 and 4×10^8 cells/kg of the recipient's body weight of T cell-depleted bone marrow cells.

The present invention also provides a method of treating a cancer using
5 mononuclear cells from a donor source into a non-autologous recipient. The method utilizes the protocol of administering mononuclear cells as described above. However, the mononuclear cells can be used to treat the cancer even in the absence of a hematopoietic cell transplantation. Thus, the step of administering hematopoietic system reconstituting cells is not necessary to treat a cancer.

10

Preferably, for treating a cancer an allogeneic transfer of mononuclear cells is utilized although the transfer can also be xenogeneic. In either context the tumor antigen or whole cells containing the antigen can be utilized to prime the donor or cells from the donor prior to transfer to the recipient. Current Protocol in Immunology ed.
15 J.E. Coligan et al., John Wiley and Sons (1994).

Any cancer can be treated using this method. These cancers include skin, brain, squamous cell carcinoma, sarcoma, esophageal, stomach, liver, kidney, colon, bladder, prostate, ovarian, uterine, testicular, neuroendocrine, bone, and pancreatic cancer. The
20 method is especially useful for hematopoietic cell cancers such as leukemias, lymphomas and multiple myeloma.

EXAMPLES

25 *Animals.* B 10 R.III (H2Kr) mice, aged eight to ten weeks, were purchased from Charles River/Jackson Laboratories. C57Bl/6 (H2Kb Thy 1.2) and BA (H2Kb Thy 1.1) mice were bred and maintained in sterile housing at the Emory University Animal Care Facility. Drinking water was acidified to a pH of 2.5.

30 *Donor Cell Preparations.* All manipulations of cells were performed with sterile Hanks Buffered Saline Solution (HBSS) containing 3% heat-inactivated fetal bovine

mice by removing the femora and tibia. The bone marrow space was flushed with medium using a 25 guage needle, followed by repeated pipetting to yield a single-cell suspension. Spleenocytes were harvested from BA (H2Kb Thy 1.1) mice by removing the spleen and placing it in a small petri dish. A single cell suspension was generated by
5 flushing the spleen with medium using a 25 gauge needle followed by repeated pipetting.

T Cell Manipulations. Bone marrow cells at a concentration of 2×10^7 cells per milliliter were incubated with biotinylated α CD3 antibody (Pharmingen, San Diego, CA) at a saturating concentration of antibody on ice for 20 minutes, then washed with ten
10 volumes of HBSS/FBS and collected by centrifugation. The cell pellets were suspended in 100 μ l of Streptavidin Microbeads (Miltenyi Biotech GmbH) and 200 μ l degassed HBSS. This solution was incubated on ice for 20 minutes, then washed as previously described. The cells were run over a Mini Macs magnetic separation column (Miltenyi Biotech, GmbH). The first fraction collected was depleted of CD3+ cells (T cell
15 depleted fraction). The column was removed from the magnetic source and CD3+ cells were eluted by washing the column with 0.5 ml HBSS/FBS.

Irradiation of spleen cells. Spleen cell suspensions were irradiated to 1000 rads in a single fraction at a dose rate of 1.462 rads/sec (0.01462 cGy/sec).
20

Antiasialo treatment. Recipient mice were injected intravenously with 100 μ l (0.1ml) of antiasialo antisera.

Irradiation and reconstitution. Recipient animals B10RJII (H2K_r) were
25 exposed to 10 Gy (1000 rads) of radiation from a Cs¹³⁷ source (Gamacell Irradiator, Canada) at a dose rate of .01462 cGy/sec (1.462 rads/sec), with the total dose being delivered in two equal fractions separated by a five hour rest. Bone marrow and spleen cell suspensions were transplanted to irradiated animals by retroorbital injection under methoxyflurane anesthesia. The recipient animals were maintained on oral aqueous
30 antibiotics (Neomycin Sulfate Polymyxin B Sulfate 6000 units/mg, Sigma Chemical, St. Louis) for four weeks after the delivery of the radiation.

Analysis of transplant recipients. Beginning at one month after transplant, mice were anesthetized with methoxyflurane and about 200 μ l of peripheral blood was collected from the retroorbital sinus into 400 μ l of HBSS plus 100 U/ml sodium heparin. A 2 ml volume of 3% Dextran T500 (Pharmacia LKB, Piscataway, NJ) in HBSS was added to each blood sample and the mixture was incubated for 20 min at room temperature to allow sedimentation of red blood cells (RBC). The upper layer of RBC-depleted fluid was transferred to a new tube. Cells were collected from this layer by centrifugation and resuspended in 2 ml of cold 0.2% NaCl for one minute followed by the addition of 2 ml of cold 1.6% NaCl to restore isotonicity. Cells were collected by centrifugation, then resuspended in HBSS/FBS at a cell concentration of approximately 1×10^6 cells/100 μ l for immunofluorescent staining. Donor and host-derived cells were distinguished with monoclonal antibodies specific for the MHC (H2Kb). Dual-color immunofluorescence, using a fluorescein-conjugated anti-Thy 1.1 reagent and allophycocyanin-conjugated anti-Thy 1.2 reagent was performed to enumerate donor-derived T cells from bone marrow (Thy 1.2) and spleen (Thy 1.1).

Results. Table 1 shows the fraction of mice surviving thirty days after receiving a lethal dose of ionizing radiation followed by intravenous infusion of a small number (500,000 cells; 0.2×10^8 cells/kg) of mouse marrow cells. The survival was greatest (80%) among mice that received bone marrow cells from genetically identical (syngeneic) litter mates, and lowest (0%) among mice that received bone marrow from genetically dissimilar (allogeneic) donors. The allogeneic donors expressed the "b" antigen on their MHC molecules while the recipients expressed the "r" antigen.

The two strains of mice are completely (fully) mismatched at the MHC antigen loci. An analogous situation in humans would be donors and patients mismatched at all six of the HLA antigen loci. It is worth noting that mortality is 60% due to graft failure and/or GvHD for genetically related human donors and patients mismatched at two out of six HLA antigens.

The survival of mice that received allogeneic bone marrow cells was increased to 80% by the co-administration of unirradiated allogeneic spleen cells; however these recipient mice were at risk for developing GvHD as assessed by the survival of large numbers (+++) of mature T cells in their peripheral blood derived from the infused spleenocytes. Mice that received allogeneic bone marrow cells in combination with irradiated spleen cells had a survival that was intermediate between the group that received syngeneic bone marrow and the group that received allogeneic bone marrow cells alone. Recipients of irradiated spleen cells did not have any detectable spleen-derived T cells in their peripheral blood, and are at much lower risk for GvHD. The addition of a single dose of irradiated spleen cells co-administered with the allogeneic bone marrow cells increased survival of recipient mice to 20%; the administration of two doses of irradiated spleen cells, (the first one day prior to the administration of allogeneic bone marrow cells and an additional dose co-administered with the allogeneic bone marrow cells) increased survival to 41%. The injection of anti-asialo antisera preceding the administration of two doses of irradiated spleen cells and the allogeneic bone marrow increased survival to 60%. The function of anti-asialo antisera is to cause *in vivo* depletion of host NK cells, further reducing the resistance of the irradiated recipient to engraftment by fully allogeneic hematopoietic reconstituting cells.

Administration of treated mononuclear cells and hematopoietic system reconstituting cells to a human subject. A patient, diagnosed with a disorder for which transplantation of hematopoietic system reconstituting cells is indicated, can be given about 5×10^6 treated mononuclear cells/kg isolated from the peripheral blood of the donor by apheresis about two days prior to the administration of the hematopoietic system reconstituting cells. After administration of the treated mononuclear cells, the patient can be given hematopoietic system reconstituting cells either in a source population of about 5×10^6 CD34+ cells/kg isolated by apheresis from the donor's peripheral blood following treatment with GCSF or an equivalent cytokine, or about 2×10^6 CD34+ cells/kg present in donor bone marrow obtained by harvesting bone marrow cells. The hematopoietic system reconstituting cells administered to the patient can be T cell-depleted or CD34+ cell-enriched from the source population.

10^6 CD34+ cells/kg present in donor bone marrow obtained by harvesting bone marrow cells. The hematopoietic system reconstituting cells administered to the patient can be T cell-depleted or CD34+ cell-enriched from the source population.

- 5 *Irradiated allogeneic donor lymphocytes have an antileukemic effect in mice without producing graft vs. host disease.* We have tested the anti-leukemic activity of irradiated allogeneic lymphocytes administered prior to and following allogeneic bone marrow transplantation (BMT) in mice. Methods: Lethally Irradiated C57BL6 (H2K, Ly 5.2) were transplanted with 0.5×10^6 T-cells depleted (TCD) BM cells from MHC mismatched B10.BR (H2K^K) donors along with a lethal dose of C1498 myeloid leukemia cells from a congenic strain of Ly 5.1 + C57BL6 mice. Allogeneic spleen cells (H2K^K) were administered 24 hours prior to BMT and then concomitantly with the TCD BM graft. Results: Mice receiving C1498 leukemia cells and TCD BM alone had a median survival time of 9 days with none of the mice surviving past day 22. The addition of two doses of 15×10^6 non-irradiated allogeneic spleen cells to mice receiving C1498 leukemia cells and TCD BM decreased the median survival time to 6 days, with mice succumbing to GvHD. The administration of two doses of 15×10^6 irradiated (7.5 Gy) allogeneic spleen cells significantly increased the median survival time to 22 days ($p < 0.01$), with 40% of recipients surviving past day 30 without evidence of leukemia. Among the mice that died in the group receiving irradiated spleen cells, 66% died of bone marrow hypoplasia and graft failure without evidence of leukemia in their blood, spleen, or bone marrow. Irradiated allogeneic lymphocytes retain an anti-leukemic activity in vivo without resulting in significant GvHD.

- 25 Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.

Table 1. 30 day survival for mice that received a lethal dose of radiation followed by transplantation with 0.5×10^6 bone marrow cells

Day -2							anti asialo anti-sera
Day 0	Syngeneic Bone marrow	Allogeneic Bone marrow	Allogeneic Bone marrow + 5×10^6 allo spleen	Allogeneic Bone marrow + 5×10^6 irradiated allo spleen	5 x 10 ⁶ irradiated allo spleen	5 x 10 ⁶ irradiated allo spleen	
Day 1						Allogeneic Bone marrow + 5×10^6 irradiated allo spleen	
Day 30 Survival (%)	80%	0%	80%	20%	41%	60%	
Number per group	n = 15	n = 24	n = 10	n = 5	n = 17	n = 20	
Donor-derived Hematopoietic Reconstruction	N/A	N/A	100%	100%	100%	100%	
Presence of T-cells from allo spleen	N/A	N/A	+++	-	-	-	

What is claimed is:

1. A method of transplanting hematopoietic system reconstituting cells from a donor source into an allogeneic recipient comprising:

a) administering to the recipient, prior to the administration of the hematopoietic system reconstituting cells, an amount of mononuclear cells which are treated so as to render them incapable of proliferating and causing a lethal graft versus host disease effect, but which are effective in enhancing subsequent engraftment of the hematopoietic system reconstituting cells in the recipient; and

b) administering to the recipient an effective amount of hematopoietic system reconstituting cells.

2. The method of claim 1, wherein the mononuclear cells are T cells.

3. The method of claim 1, wherein the mononuclear cells are natural killer cells.

4. The method of claim 1, wherein the mononuclear cells are a mixture of T cells and natural killer cells.

5. The method of claim 1, further comprising depleting the recipient's T cells and natural killer cells prior to administration of the hematopoietic system reconstituting cells.

6. The method of claim 1, wherein the mononuclear cells are treated by exposure to a source of ionizing radiation.

7. The method of claim 6, wherein the source of ionizing radiation is gamma radiation produced by the nuclear decay of a radio-isotope.

8. The method of claim 6, wherein the source of ionizing radiation is a linear accelerator which produces high energy X-rays.

9. The method of claim 6, wherein the amount of irradiation is between 250 and 2000 rads.

10. The method of claim 6, wherein the amount of irradiation is between 500 and 1500 rads.

11. The method of claim 6, wherein the amount of irradiation is between 500 and 1000 rads.

12. The method of claim 1, wherein the treated mononuclear cells are administered to the recipient up to ten days prior to administration of the hematopoietic system reconstituting cells.

13. The method of claim 1, wherein the treated mononuclear cells are administered to the recipient between one and five days prior to the administration of the hematopoietic system reconstituting cells.

14. The method of claim 1, wherein the hematopoietic system reconstituting cells and the treated mononuclear cells are from the same donor source.

15. The method of claim 1, wherein the amount of treated mononuclear cells administered to the recipient is between 0.05×10^6 and 30×10^6 cells/kg of the recipient's body weight.

16. The method of claim 1, wherein the hematopoietic system reconstituting cells administered to the recipient are present in a source population of between 0.2×10^8 and 4.0×10^8 donor bone marrow cells/kg of recipient's body weight.

17. The method of claim 1, wherein the hematopoietic system reconstituting cells administered to the recipient are present in a source population of between 1.0×10^8 and 40×10^8 donor cytokine mobilized peripheral blood stem cells/kg of recipient's body weight.

18. The method of claim 1, wherein the hematopoietic system reconstituting cells that are administered to the recipient are T cell-depleted.

19. The method of claim 1, wherein the hematopoietic system reconstituting cells that are administered to the recipient are hematopoietic stem cell enriched from the source population.

20. A method of transplanting bone marrow cells into an allogeneic recipient comprising;

a) administering to the recipient, one to five days prior to administration of the bone marrow cells, between 0.05×10^6 and 30×10^6 cells/kg of body weight of T cells that have been exposed to between 500 and 1000 rads of irradiation; and

b) administering to the recipient between 1.0×10^8 and 4×10^8 T cell-depleted bone marrow cells/kilogram recipient's body weight.

21. The method of claim 1, wherein the hematopoietic system reconstituting cells also produce an anti-leukemia effect in the recipient.

22. A method of treating a cancer using mononuclear cells from a donor source into a non-autologous recipient comprising administering to the recipient an amount of mononuclear cells which are treated so as to render them incapable of proliferating and causing a lethal graft versus host disease effect, but which are effective in treating the cancer in the recipient.

23. The method of claim 22, wherein the mononuclear cells are T cells.

24. The method of claim 22, wherein the mononuclear cells are natural killer cells.

25. The method of claim 22, wherein the mononuclear cells are a mixture of T cells and natural killer cells.

26. The method of claim 22, wherein recipient is allogeneic.

27. The method of claim 22, wherein the mononuclear cells are treated by exposure to a source of ionizing radiation.

28. The method of claim 27, wherein the source of ionizing radiation is gamma radiation produced by the nuclear decay of a radio-isotope.

29. The method of claim 27, wherein the source of ionizing radiation is a linear accelerator which produces high energy X-rays.

30. The method of claim 27, wherein the amount of irradiation is between 250 and 2000 rads.

31. The method of claim 27, wherein the amount of irradiation is between 500 and 1500 rads.

32. The method of claim 27, wherein the amount of irradiation is between 500 and 1000 rads.

33. The method of claim 22, wherein the amount of treated mononuclear cells administered to the recipient is between 0.05×10^6 and 30×10^6 cells/kg of the recipient's body weight.

34. The method of claim 22, wherein the cancer is a hematopoietic cell cancer.

35. The method of claim 36, wherein the hematopoietic cell cancer is leukemia.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 96/12426

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K35/14 A61K35/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ACTA HAEMATOLOGICA, vol. 77, no. 4, 1987, pages 208-214, XP000608627 GRATWOHL ET AL: "ENGRAFTMENT OF T-CELL-DEPLETED RABBIT BONE MARROW" cited in the application see page 208,abstract; pages 212-213,discussion ---	1-21
X	BONE MARROW TRANSPLANTATION, vol. 3, 1988, pages 577-582, XP000608628 GRATWOHL ET AL: "IRRADIATED DONOR BUFFY COAT FOLLOWING T CELL-DEPLETED BONE MARROW TRANSPLANTS" cited in the application see page 577,abstract and first 3 paragraphs; pages 579 and 581,'discussion' --- -/-	1-21

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *A* document member of the same patent family

Date of the actual completion of the international search

8 November 1996

Date of mailing of the international search report

22.11.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Sitch, W

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/US 96/12426

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>BLOOD, vol. 78, 1991, pages 3317-3322, XP000608936 COHN ET AL: "HEMATOPOIETIC RECONSTITUTION AND PREVENTION OF GRAFT-VERSUS-HOST DISEASE WITH UVB-IRRADIATED HAPLOIDENTICAL MURINE SPLEEN AND MARROW CELLS" cited in the application see page 3317,abstract; pages 3320-3321,'discussion'</p> <p style="text-align: center;">---</p>	1-21
X	<p>INDIAN JOURNAL OF MEDICAL RESEARCH (B), vol. 98, 1993, pages 1-7, XP000608934 KOCHUPILLAI: "EMERGING CONCEPTS IN THE MANAGEMENT OF ACUTE LYMPHOBLASTIC LEUKAEMIA" see page 1,abstract; page 4-page 5,'bone marrow transplantation'</p> <p style="text-align: center;">---</p>	22-35
X	<p>WO,A,92 10198 (JOHNSON & JOHNSON RESEARCH PTY) 25 June 1992 see page 4, line 38 - page 7, line 28</p> <p style="text-align: center;">---</p>	22-35
X	<p>WO,A,94 26284 (WISTAR INST ;SANTOLI DANIELA (US); ROVERIA GIOVANNI (US); CESANO A) 24 November 1994 see page 11, line 32 - page 12, line 14 see page 21, line 27 - page 24, line 32</p> <p style="text-align: center;">---</p>	22-35
A	<p>TRANSPLANTATION, vol. 6, no. 4, 1968, pages 587-593, XP000607902 STORB ET AL: "MARROW GRAFTS BY COMBINED MARROW AND LEUKOCYTE INFUSIONS IN UNRELATED DOGS SELECTED BY HISTOCOMPATIBILITY TYPING" cited in the application see page 591-592,'discussion'</p> <p style="text-align: center;">---</p>	1-21
A	<p>BLOOD, vol. 53, no. 4, 1979, pages 552-557, XP000608626 DEEG ET AL: "ABROGATION OF RESISTANCE TO AND ENHANCEMENT OF DLA-NONIDENTICAL UNRELATED MARROW GRAFTS IN LETHALLY IRRADIATED DOGS BY THORACIC DUCT LYMPHOCYTES" cited in the application see page 552,abstract</p> <p style="text-align: center;">---</p>	1-21

-/--

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/12426

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BLOOD, vol. 59, no. 2, 1982, pages 236-246, XP000608625 STORB ET AL: "MARROW TRANSPLANTATION WITH OR WITHOUT DONOR BUFFY COAT CELLS FOR 65 TRANSFUSED APLASTIC ANEMIA PATIENTS" cited in the application see page 236,abstract ---	1-21
A	WO,A,95 12404 (YEDA RES & DEV ;RYCUS AVIGAIL (IL)) 11 May 1995 see page 3, paragraph 3 - paragraph 4 ---	1-21
A	US,A,5 147 289 (EDELSON RICHARD L) 15 September 1992 see column 4, line 11 - line 27 ---	22-35
A	WO,A,95 24910 (BAXTER INT ;HADASIT MED RES SERVICE (IL); SLAVIN SHIMON (IL)) 21 September 1995 see page 4, line 26 - page 9, line 10 -----	1-35

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/ 12426

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 1 - 35
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 96/12426

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9210198	25-06-92	NONE	
WO-A-9426284	24-11-94	AU-A- 6912694	12-12-94
		CA-A- 2162732	24-11-94
		EP-A- 0697875	28-02-96
WO-A-9512404	11-05-95	AU-A- 1087295	23-05-95
US-A-5147289	15-09-92	US-A- 5383847	24-01-95
WO-A-9524910	21-09-95	AU-A- 2100695	03-10-95

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.